Time, Labor, and Social Domination: A Reinterpretation of Marx's Critical Theory (Volume 0)

In this ambitious book, Moishe Postone undertakes a fundamental reinterpretation of Marx's mature critical theory. He calls into question many of the presuppositions of traditional Marxist analyses and offers new interpretations of Marx's central arguments. These interpretations lead him to a very different analysis of the nature and problems of capitalism and provide the basis for a critique of "actually existing socialism." According to this new interpretation, Marx identifies the central core of the capitalist system with an impersonal form of social domination generated by labor itself and not simply with market mechanisms and private property. Proletarian labor and the industrial production process are characterized as expressions of domination rather than as means of human emancipation. This reformulation relates the form of economic growth and the structure of social labor in modern society to the alienation and domination at the heart of capitalism. It provides the foundation for a critical social theory that is more adequate to late twentieth-century capitalism.

Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and upon Merck & Co., Inc., which merged with Sharp & Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw extensively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals.